The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 07, 2014
Filed:
Apr. 01, 2009
Riccardo Giovannini, Verona, IT;
Cornelia Dorner-ciossek, Warthausen, DE;
Christian Eickmeier, Mittelbiberach, DE;
Dennis Fiegen, Biberach, DE;
Thomas Fox, Biberach, DE;
Klaus Fuchs, Mittelbiberach, DE;
Niklas Heine, Biberach, DE;
Holger Rosenbrock, Mittelbiberach, DE;
Gerhard Schaenzle, Biberach, DE;
Riccardo Giovannini, Verona, IT;
Cornelia Dorner-Ciossek, Warthausen, DE;
Christian Eickmeier, Mittelbiberach, DE;
Dennis Fiegen, Biberach, DE;
Thomas Fox, Biberach, DE;
Klaus Fuchs, Mittelbiberach, DE;
Niklas Heine, Biberach, DE;
Holger Rosenbrock, Mittelbiberach, DE;
Gerhard Schaenzle, Biberach, DE;
Boehringer Ingelheim International GmbH, Ingelheim am Rhein, DE;
Abstract
The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, Formula (I) with is a mono-, bi- or tri-cyclic heterocyclyl group, the ring members of which are carbon atoms and at least 1, preferably 1, 2 or 3, heteroatom(s), which are selected from the group of nitrogen, oxygen and sulphur, which is in the form of —S(O)— with r being 0, 1 or 2, and—said heterocyclyl group is or comprises 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member and—said heterocyclyl group is bound to the scaffold by said 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.